Dextech Medical

Dextech Medical EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical (DEX.SL) as of Oct 20, 2026 is -35.07 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -21.19 % — a change of 65.54% (lower).

EBIT/Assets

-35.07 %

YoY

65.54%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical is 2026 -35.07 % . Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical was 2025 -21.19 % . It decreases by 65.54% lower compared to the previous year.

The Dextech Medical EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-37.25 SEK
Jan 1, 2020
-57.81 SEK
Jan 1, 2021
-83.98 SEK
Jan 1, 2022
-13.31 SEK
Jan 1, 2023
-14.10 SEK
Jan 1, 2024
-18.14 SEK
Jan 1, 2025
-21.19 SEK
Jan 1, 2026
-35.07 SEK
The Dextech Medical EBIT/Assets history
YEAREBIT/AssetsYoY
-35.07 %+65.54%
-21.19 %+16.79%
-18.14 %+28.66%
-14.10 %+5.93%
-13.31 %-84.15%
-83.98 %+45.28%
-57.81 %+55.18%
-37.25 %-12.24%
-42.44 %+60.26%
-26.48 %-0.44%
-26.60 %+37.21%
-19.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dextech Medical Stock analysis

What does Dextech Medical do? Dextech Medical AB develops drug candidates for urological oncology, focusing on prostate cancer and other conditions. The company utilizes its patented GuaDex technology platform to create modified carbohydrate molecules combined with active substances. Its portfolio includes OsteoDex for bone metastases in castration-resistant prostate cancer, SomaDex targeting acromegaly and neuroendocrine tumors, and CatDex for bladder cancer treatment. The company holds patents or patent applications for these three drug candidates. Dextech Medical AB's primary revenue streams come from licensing its technology and drug candidates to pharmaceutical partners. The company's GuaDex platform and its drug candidates, OsteoDex, SomaDex, and CatDex, are marketed to biopharmaceutical companies seeking innovative treatments for urological oncology and related diseases. The firm's focus on prostate cancer, bone metastases, and bladder cancer creates a targeted market for its products. The company's business model relies on developing and commercializing its drug candidates through partnerships with established pharmaceutical companies. With only three drug candidates in its portfolio, Dextech Medical AB targets specific therapeutic areas within urological oncology, leveraging its patented GuaDex platform to attract potential partners in the biopharmaceutical industry. Dextech Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dextech Medical stock

Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical is -35.07 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Dextech Medical changed from -21.19 % to -35.07 %, representing a 65.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Dextech Medical since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Dextech Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Dextech Medical

All Key Metrics — Dextech Medical